2 February 2017 - The development of medicinal products has been shifting towards a value-driven model. 

However, although companies need to engage with health technology assessment (HTA) bodies to inform effective strategies to gain market access for their new medicinal products, HTA scientific advice (SA) procedures are not yet routine steps in the clinical development program.

Read Nature Reviews Drug Discovery article [subscription required]